Mary Anne Heino
President and Chief Executive Officer
Mary Anne Heino brings to Lantheus 30 years of diverse pharmaceutical industry experience. Joining Lantheus in April 2013 as Chief Commercial Officer, Ms. Heino was promoted to Chief Operating Officer in March 2015 and to President and Chief Executive Officer in August 2015. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing. Before that, Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson Company, including Vice President Strategic Planning and Competitive Intelligence, Vice President Sales, Executive Director Customer Relationship Management and Senior Director Immunology Marketing. Ms. Heino began her professional career with Janssen Pharmaceutica as a Sales Representative in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master’s in Business Administration from the Stern School of Business at New York University. She earned a Bachelor’s of Science in Nursing from the City University of New York and a Bachelor’s of Science in Biology from the State University of New York at Stony Brook. She is currently on the Board of Directors for MassMEDIC, an industry association that serves the MedTech community of Massachusetts, and serves on the Executive Committee for the Massachusetts Business Roundtable (MBR).
Robert J. Marshall Jr.
Chief Financial Officer and Treasurer
Robert J. Marshall Jr. joined Lantheus as Chief Financial Officer and Treasurer in September 2018. Mr. Marshall brings to the Company more than 30 years of finance experience, including in M&A, capital markets and investor relations. Prior to joining Lantheus, Mr. Marshall spent 16 years with Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a global medical device company with a leading position in musculoskeletal health. He held various senior leadership roles, including Vice President, Investor Relations and Corporate Treasurer, and most recently as Vice President, Americas Finance, for the U.S., Canadian and Latin American commercial markets. Prior to Zimmer Biomet, Bob was employed with Brown & Williamson Tobacco, a subsidiary of British American Tobacco, p.l.c., in Louisville, Kentucky, where he held several positions of increasing responsibility. Mr. Marshall holds a Master of Business Administration from Indiana University, South Bend, and a Bachelor of Business Administration in Finance from the University of Notre Dame. Bob also holds the CFA designation.
Chief Operations Officer
John Bolla brings to Lantheus more than 22 years of diverse supply chain, operations and manufacturing experience in the pharmaceutical industry. He was promoted to Chief Operations Officer in March 2019. As Chief Operations Officer, Mr. Bolla leads the Company’s Technical Operations, Engineering & Facilities, Environment, Health & Safety, Human Resources, and Information Technology organizations in addition to his oversight of the Puerto Rico business unit. Mr. Bolla joined Lantheus as Senior Vice President of Technical Operations in May 2018.
Prior to joining Lantheus, Mr. Bolla spent 20 years at GlaxoSmithKline plc (GSK), a global branded pharmaceutical company. He held various senior leadership roles, including Vice President, Supply Chain, North America, where he was responsible for leading all manufacturing, supply planning, logistics and distribution for GSK’s largest global market. He also held senior roles as Vice President and Site General Manager for a large GSK manufacturing facility in the U.S. as well as Vice President and Global Head of External Supply and Global Contract Manufacturing. He has also served in multiple senior Procurement leadership roles at GSK.
Mr. Bolla holds a Bachelor of Science in Business Administration/Accounting from The University of Central Florida.
Senior Vice President - Law and Public Policy, General Counsel
Michael (Mike) Duffy serves as Lantheus’ Senior Vice President – Law and Public Policy, General Counsel. He joined Lantheus in 2008 and previously served as Senior Vice President – Strategy and Business Development, General Counsel and Secretary. Prior to joining Lantheus, he served as Senior Vice President, General Counsel and Secretary of Point Therapeutics, Inc., a Boston-based biopharmaceutical company, and as Senior Vice President, General Counsel and Secretary of Digital Broadband Communications, Inc., a competitive local exchange carrier. Additionally, Mr. Duffy served as Senior Vice President, General Counsel and Secretary of ETC w/tci, a sub-portfolio of TCI Ventures, Inc./Liberty Media Corporation. Mr. Duffy began his legal career with the law firm Ropes & Gray and holds law degrees from the University of Pennsylvania and Oxford University and a Bachelor of Arts in History of Science from Harvard College. Mr. Duffy also previously served as the Chairman of the Board of Directors of CORAR, the Council on Radionuclides and Radiopharmaceuticals, a trade association for the radiopharmaceutical industry.
Sarah Le Roy
Senior Vice President, Human Resources
Sarah Le Roy has served as Senior Vice President, Human Resources since April 2018. She joined Lantheus in January 2018 as Vice President, Human Resources. She brings to the company more than 20 years of experience serving as a results-focused Human Resources leader for global companies across a variety of industries. Sarah most recently served as Executive Vice President Organizational Strategy for Fike Corporation, a privately held, globally recognized supplier of products and services that protect people and critical assets from dangers such as fire and explosion, where she was responsible for leading all Human Resources, Legal, and Corporate Communications activities across the globe. Prior to that, Sarah worked as Vice President, Talent Management, Head of Talent and Assessment Practices and Co-Head of the High Performance Team Practice for Linkage, Inc., a global organizational development company. Earlier in her career, she held a variety of Human Resources, organizational learning, executive search and recruiting positions. Sarah received an MBA/MSC in Business from the MIT Sloan School of Management and a Bachelor of Arts from Williams College.
Senior Vice President, Corporate Development
Etienne Montagut joined Lantheus as Senior Vice President, Corporate Development in September 2018. Mr. Montagut brings to the Company more than 20 years of commercial, portfolio management and business development & licensing experience. Prior to joining Lantheus, Mr. Montagut spent the last six years with GE Healthcare, the $19 billion healthcare business of GE (NYSE: GE) and a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies. He held various senior leadership roles at GE Healthcare, including General Manager, Global SPECT Portfolio & Director of Cardiology, Executive, Global Product Leader SPECT Neurology & Cardiology, and most recently as Executive, General Manager Molecular Imaging Greater China. Prior to GE Healthcare, while at Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group focused on innovation and specialty care, Mr. Montagut held both commercial and corporate positions, including Corporate Commercial Development, Business Development & Licensing and Portfolio Management. Mr. Montagut holds a Master of Business Administration from Imperial College, London, and a Master of Business Intelligence from EGE in Paris.
Cesare Orlandi, MD
Chief Medical Officer
Dr. Cesare (Ces) Orlandi joined Lantheus in March 2013 as Chief Medical Officer. Ces brings to the company more than 20 years of diverse pharmaceutical industry experience with a proven track record of directing successful drug development programs, providing leadership in product pipeline portfolio management and overseeing interactions with regulatory agencies. Ces most recently served as Senior Vice President and Chief Medical Officer of TransTech Pharma, Inc., a clinical-stage pharmaceutical company, where he led drug development from Phase 1 through Phase 3 trials for the company’s pipeline programs. Prior to joining TransTech, Ces served as the Senior Vice President and Chief Medical Officer of Cardiokine, Inc., a specialty pharmaceutical company, completing the late stage development of lixivaptan, a Phase 3 program in 20 countries and over 500 sites worldwide. Earlier in his career, he worked with Otsuka Pharmaceuticals, Medco Research Inc. and the Radiopharmaceutical Division of Du Pont Merck Pharmaceutical Company, which is now Lantheus Medical Imaging. Ces received his medical degree with honors from the University of Pavia Medical School, Pavia, Italy. He is currently an Adjunct Assistant Professor of Medicine at Tufts University School of Medicine, Boston.
Simon Robinson, Ph.D.
Senior Vice President, Research and Pharmaceutical Development
Simon Robinson has served as Senior Vice President, Research and Pharmaceutical Development since April 2018. He previously served as Vice President, Research and Pharmaceutical Development from 2010 to 2018. Prior to that, he served as Senior Director, Discovery Research from 2008 to 2010 and Director, Discovery Biology and Veterinary Sciences from 2001 to 2008. Before joining Lantheus, he held research positions at Bristol-Myers Squibb, Sphinx Pharmaceuticals, BASF and DuPont Pharmaceuticals. Simon has more than 80 publications and is listed as an inventor on 19 U.S. patents. He holds a Ph.D. and Bachelor of Science Pharmacology from the University of Leeds, England and performed his post-doctoral training at the University of Wisconsin Clinical Cancer Center.
Senior Vice President, Quality
Carol Walker has served as Senior Vice President, Quality since April 2018. She has overseen our Environment, Health and Safety department since December 2017. She joined Lantheus in February 2015 as Vice President, Quality. Carol brings more than 30 years of industry experience in quality and medical technology primarily in the medical device area. Prior to joining Lantheus, she served as Vice President of Quality Assurance and Regulatory Affairs for Intelligent Medical Devices, Inc. (IMDx), a company that designs, develops and manufactures in vitro diagnostic devices. Prior to that, Carol spent 11 years with Siemens Healthcare Diagnostics where she held positions of increasing responsibility, including Vice President of Quality Assurance. Earlier in her career, Carol held a variety of quality control positions during her 15 year tenure with Nova Biomedical, one of the 25 largest in vitro diagnostic companies in the world. Carol received a Bachelor of Science in Medical Technology from the Rochester Institute of Technology.